Aptevo Therapeutics Inc.
APVO · XNASCIK 1671584fmd_0BZ5KEQFVJRND7WE2N5ZAX4GXXManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2015 to Jun 30, 2026, 46 periods
| Line item | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenues | 10 | 15 | 23 | 32 | 4 | 12 | 3 | – | – | – |
| Cost of revenue | 12 | 5 | 11 | 20 | – | – | – | – | – | – |
| Gross profit | (2) | 10 | 12 | 12 | – | – | – | – | – | – |
| Research and development | 29 | 29 | 35 | 25 | 18 | 19 | 18 | 17 | 14 | 15 |
| Selling, general and administrative | 36 | 35 | 28 | 25 | – | – | – | – | – | – |
| Operating income | (139) | (54) | (52) | (41) | (27) | (21) | (29) | (29) | (25) | (26) |
| Other non-operating income (expense) | (1) | (2) | (2) | (2) | (1) | (8) | (4) | 1 | 0 | 0 |
| Income before taxes | (140) | (56) | (54) | (43) | (31) | (29) | 7 | (19) | (24) | (26) |
| Income tax expense | (20) | (23) | – | – | – | – | – | – | – | 0 |
| Net income from continuing operations | (120) | (33) | (54) | (43) | (31) | (29) | 7 | (19) | (24) | (26) |
| Net income | (112) | 7 | (54) | (40) | (18) | (28) | 8 | (17) | (24) | (26) |
| Net income to common shareholders | – | – | – | – | – | – | – | – | (24) | (28) |